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ABSTRACT
Objectives: Comparison of the ability to inhibit alloactivated lymphocytes proliferation of human Wharton Jelly (WJ) and 
amniotic membrane (AM) mesenchymal stem cells (MSCs) from preterm and term pregnancies.
Material and methods: Term-WJ-MSCs (n = 5) and Preterm-WJ-MSCs (n = 1) were obtained from tissue explants by adherent 
method. Term-AM-MSCs (n = 5) and Preterm-AM-MSCs (n = 1) were obtained by tripsin and collagenase digestion method. 
Term and Preterm MSCs phenotype was confirmed in vitro by flow cytometry. To evaluate the potential of fetal and adult 
MSCs to diminish immunological response mixed lymphocytes reaction (MLR) has been performed.
Results: Term and Preterm cells were positively identified as MSCs by the expression of CD73 and CD90 and CD105 with 
simultaneous absence of CD11b, CD14, CD19, CD34, CD45 and HLA-DR. The mean inhibition of allostimulated lymphocytes 
after addition of fetal derived MSCs amounted 64.8% for term AM-MSCs and 42.1% for term WJ-MSCs (for both populations 
the effect was statistically significant, p < 0.01). The addition of preterm-MSCs to MLR resulted in reduction of stimulated 
lymphocytes proliferation by 64.9% for AM-MSCs and 86.1% for WJ-MSCs.
Conclusions: Presented results suggest that preterm fetal tissues contain MSCs which posses similar immunosuppressive 
capacity as those from term pregnancies. In the future MSCs from the umbilical cord and amnion can be potentially used 
to prevent immuno-dependent injuries in premature newborns. 
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INTRODUCTION
The recent progress in clinical translation of basic stem 
cell research is based on two main types of human cells: 
Pluripotent stem cells (embryonic or induced) and mesen-
chymal stem cells (MSCs). With the advance of science we 
currently know MSCs have different characteristic depend-
ing on the tissue they originate, donor age and culture 
conditions [1–3]. Therefore, the key challenge for research-
ers remain fitting best type of stem cells for specific thera-
pies. MSCs derived from fetal tissues such as Wharton Jelly 
(WJ-MSCs) and amniotic membrane (AM-MSCs) are very 
promising for vide spectrum of applications. Numerous 
data indicate that these early-stage cells exert significantly 
lower immunogenicity but similar immunomodulatory and 
neuroprotective potential when compared to cells derived 
from mature tissues [2, 4]. It was demonstrated, that MSCs 
isolated from perinatal tissues not only fulfill general charac-
teristics of MSCs [2, 5, 6], but present higher proliferative po-
tential and less typical signs of senescence at an early stage 
in comparison to adult, bone marrow or adipose derived 
MSCs [2, 7]. Although the mechanism of MSCs therapeutic 
action is not fully elucidated, there is mounting evidence 
that paracrine enhancement of endogenous regenerative 
potential and selective modulation of immune system is 
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predominantly responsible for the vast MSCs effects after 
transplantation, not as previously thought simple replace-
ment of damaged tissue [8, 9].
This feature can and should be introduced in prevention 
and treatment of perinatal brain hemorrhage and acute 
respiratory syndrome associated with preterm deliver-
ies. The use of autologous MSCs from fetal tissues gives 
opportunity to prompt start of the therapy, without the 
burden of matching recipient and the donor. Our previous 
research has proven that fetal derived MSCs from WJ and 
AM have different, but promising cytokine profile and both 
share the capacity to inhibit proliferation of allo-activated 
lymphocytes in an in vitro transplantation model [2]. It is 
known that fetal MSCs obtained from fetal tissues from term 
pregnancies complicated with preeclampsia have similar 
features when compared with healthy pregnancies [10]. 
In current research we try to find out if immature tissues 
obtained from preterm delivery are rich in MSCs with similar 
immunomodulative properties as ones from term deliveries. 
MATERIAL AND METHODS 
Amniotic membrane and umbilical cord donation
Ethical approval was received from the Medical Univer-
sity of Warsaw Ethics Committee and informed consent was 
obtained from all women who donated tissues for the experi- 
ment. Amniotic membrane (AM, 10 cm2) and umbilical cord 
(WJ, 10 cm) samples were taken from 5 healthy pregnant 
patients undergoing scheduled cesarean section at term 
of delivery, and one patient who had premature delivery at 
29 weeks due to spontaneous contractions. Similar to our 
previous experiments AM and WJ fragments were placed in 
sterile containers with PBS + 1% penicillin and streptomycin 
solution, and transferred to the laboratory unit within 1 to 
2 hours. All further stages of isolation and cell culture were 
performed under a laminar flow hood. 
Amniotic membrane
Amnion layer was mechanically separated from the cho-
rion and, after rinsing of blood and debris it was immersed 
in 70% ethanol solution for 3 seconds to eliminate potential 
fungal or bacterial contamination. Tissue was washed twice 
in standard Phosphate Buffered Saline (PBS) and incubated 
in 0.25% trypsin-EDTA solution (Gibco) for 1 h in 37°C with 
continuous stirring on roller mixer, washed again in PBS and 
exposed to 1 mg/mL collagenase type I (Sigma-Aldrich), 
C0130)/0.025mg/mL DNAse (Sigma-Aldrich) solution. The 
membrane was incubated in 37°C for 60 to 90 minutes 
until complete tissue disintegration. The released cells were 
centrifuged, washed twice, suspended in growth medium 
(GM) consisting of DMEM-LG (Dulbecco’s modified Eagle’s 
Medium with low glucose; Lonza) supplemented with fetal 
calf serum (FCS; 15%; Lonza) and antibiotic-antimycotic solu-
tion (Penicillin-streptomycin-amfoterycin; 1.5%; Invitrogen), 
and seeded on Ø 100 mm culture dish (BD PrimariaTM). 
After 48 hours the dishes were washed with PBS to remove 
non-adherent cells and debris and suspended in GM again. 
When primary cultures reached subconfluency, cells were 
detached by short trypsinisation (2 min in 0.25% trypsin 
with 1mM EDTA; Invitrogen) and replated at a density of 
5.0 × 103 cells/cm2 for further growth.
Wharton Jelly 
Collected umbilical cord fragments were washed from 
blood, devascularised and cut with sterile surgical knife into 
about 3 mm3 fragments and placed on Ø 100 mm culture 
dish (BD PrimariaTM) in GM and cultured in 37°C and 5% 
CO2 atmosphere. The medium was changed every 2–3 days 
without touching the explants. After 10 days, the explants 
were collected, the dishes washed to remove non-adherent 
cells and debris. The MSCs cells which migrated from the WJ 
explants were detached from the culture dish and reseeded 
on a new dish in a density of 5.0 × 103 cells/cm2 for further 
growth.
All experiments were performed on cells (all types) be-
tween passage 3 and 5. 
Flow cytometry, differentiation assay,  
and morphology of acquired cells 
The criteria of human MSCs identification established 
in 2006 by the International Society for Cell Therapy were 
tested. Both, WJ and AM-derived cells displayed typical MSCs 
spindle shape morphology and created colonies on plastic 
surface regardless of fetal tissues maturity. To evaluated 
the multipotency of isolated MSCs, cells were induced to 
differentiate into adipocytes, osteocytes and chondrocytes 
using adequate differentiation media according to manufac-
turer protocols (Human Mesenchymal Stem Cell Functional 
Identification Kit; R&D Biosystems, Minneapolis, USA). MSCs 
osteogenic potential was then confirmed by staining mi- 
neral deposits with Alizarin Red solution (Sigma-Aldrich). 
Lipid droplets accumulated by adipocytes were visualized 
with Oil Red O solution (Sigma-Aldrich). To prove the induc-
tion of chondrogenesis in MSCs, toluidine blue staining was 
performed, in which cartilaginous extracellular matrix was 
stained purple (metachromasia). The results of differentia-
tion is shown on Figure 1. The immunophenotype of MSCs 
was assessed by flow cytometry, using Human MSCs Analysis 
Kit (BD Stemflow) for the presence of cell surface antigens 
CD73, CD90, CD105, and the absence of CD34, CD45, CD11b, 
CD19 and HLA-DR. 
Mixed lymphocytes reaction (MLR)
One of approved methods to confirm MSCs immuno- 
suppressive potential is to assess their capacity to inhibit 
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proliferation of allo-activated lymphocytes in Mixed Lym-
phocyte Reaction (MLR) [11]. At first peripheral blood mono-
nuclear cells (PBMCs) were isolated from venous blood of 
healthy blood donors by density gradient centrifugation 
onto Histopaque-1077 (Sigma Aldrich). Half of the isolated 
PBMCs from each donor were inactivated by gamma ir-
radiation for 90 min. 
MLR aims to measure the proliferation rate of lympho-
cytes from donor A in the response to lymphocytes from 
unrelated donor B. To assess activity of lymphocyte from 
a certain donor, one population was always irradiated 
(marked as “x”). Therefore, cells were tested in the follow-
ing combinations: ABx and BAx. The basic proliferation level 
was measured by control combinations: AAx and BBx To 
evaluate the in vitro immunosuppressive potential of MSCs, 
they were added to the mixture of lymphocytes from donors 
A and B (PBMCs donors were unrelated to MSCs donor). 
The experiments were performed on a 96-well flat-bottom 
plates (Greiner). Lymphocytes were seeded in concentra-
tion of 1 × 105 cells/well per donor and were cultured with 
or without addition of MSCs (1 × 104/well). PBMCs cultures 
without MSCs were used as controls. Cells were cultured 
for 5 days at 37ºC in a humidified atmosphere with 5% 
CO2. After 5 days, the cells were pulsed with 1 μCi/well of 
3H-thymidine (113 Ci/nmol, NEN) for the last 18 hours of the 
incubation and harvested with an automated cell harvester 
(Skatron). The amount of 3H-thymidine incorporated into 
the cells was measured using a Wallac Microbeta scintilla-
tion counter (Wallac), giving the level of radioactivity as 
‘Corrected Counts per Minute’ (CCPM). Experiments were 
performed in triplicates. 
Statistical method
Statistical analysis was performed in order to evalu-
ate the significance of term MSCs effect on lymphocyte 
proliferation in MLR. The data distribution was assessed 
using Shapiro-Wilk test. Due to abnormal distribution and 
limited size of analyzed groups (n = 10), non-parametric 
Wilcoxon matched-pairs signed-ranks test was used. A level 
of significance was set at p < 0.05.
RESULTS 
Expression of surface markers  
in MSCs using flow cytometry analysis
The cluster of differentiation antigens (CD) profiles of cul-
tured cells were rated by flow cytometry after 3–4 passages. It 
was found that mean expression of CD73, CD90, CD105 sur-
face markers with simultaneous absence of: CD11b, CD14, 
CD19, CD34, CD45 and HLA-DR was for term AM-MSCs 72.1% 
(median 87.6%, SD = 0.22). In this population, a mean of 
90.6% (median 91.6%, SD = 0.13) has been positive for CD44, 
an additional MSCs marker. In preterm AM-MSCs samples, the 
mean values were even better — 96.2% and 94.1% respec-
tively. The results for WJ-MSCs was similar and can be seen 
in Table 1. Despite the same procedures and conditions, the 
tempo of culture varied between samples due to ontogenic 
dfifferences, but in the case of premature AM we were able 
to harvest 8 million of MSCs after 7 days from the delivery. 
Figure 1. Bright field images. Both amnion-derived (upper row) and umbilical cord-derived (lower row) can be differentiated into adipocytes  
(A, D — intracellular fat deposits stained in red), osteoblasts (B, E — calcium deposits in cellular walls stained in red), and chondroblasts  
(C, F — cartilaginous extracellular matrix stained purple). Scale bars: 20 µm (A, D), 50 µm (B, C, E, F)
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MSCs from premature tissues share 
immunosuppressive properties of term fetal MSCs
Premature MSCs inhibit proliferation of lymphocytes 
stimulated by PBMCs from the unrelated donor  
in similar way as cells derived at term
Mixing allogenic, irradiated PBMCs from two donors 
results in a massive increase in lymphocytes proliferation 
(p < 0.01 in comparison to auto-stimulated cells). The addi-
tion of MSCs to MLR, regardless of the source, inhibited stim-
ulation of lymphocytes. For term WJ-MSCs the mean prolif-
eration of PBMCs [CCPMx103] dropped from 786 (± 127.6) 
to 388 (± 84.3), for term AM-MSCs form 1242 (± 331) to 329 
(± 76.75), for preterm WJ-MSCs from 584 (± 130) to 86 (± 3.2), 
and preterm AM-MSCs from 1059 (± 244) to 358 (± 46). Data 
are presented on Figures 2 and 3. For each term MSCs type, 
the inhibition of PBMCs proliferation was statistically signifi-
cant at the level of 1%; for term AM-MSCs p = 0,005 (Wil-
coxon test), for term WJ-MSCs p = 0,004 (Wilcoxon test). The 
level of MLR inhibition induced by preterm MSCs did not 
differ from term MSCs, regardless of tissue type. 
Figure 3. The effect of adding term and preterm WJ-MSC’s to MLR, 
Addition of term MSC’s leads to significant decline in lymphocytes 
proliferation with p = 0.004 (Wilcoxon test). The effect of preterm cells 
is equally good
Table 1. MSC’s antigen profiles in flow cytometry
Preterm WJ-
MSCs
Preterm AM-
MSCs
Term WJ-MSCs 
[mean value]
Term AM-MSCs 
[mean value]
Term WJ-MSCs 
[median value]
Term AM-MSCs 
[median value]
1. CD73, CD90, 
CD105 (+) 92.60% 96.20% 79.60% 72.20% 92.80% 87.60%
2. CD11b, CD14, 
CD19, CD34, CD45, 
HLA-DR (–)
96.70% 94.10% 86.78% 90.60% 88.05% 91.60%
SD1 0.197456 0.239502 0.154108 0.218873
SD2 0.11004 0.103928 0.207586 0.126619
The extend of MLR inhibition does not differ between 
analyzed MSCs types
The mean inhibition of proliferation rate after addition 
of premature MSCs to the MLR is similar to MSCs derived at 
term. To avoid distortion of the results due to individual dif-
ferences in donor’s lymphocytes activity we calculated ‘MLR 
ratio’ by dividing the result of allo-stimulation by allo-sti- 
mulation with MSCs. Mean MLR ratio for Term-AM-MSCs was 
3.12 and for Preterm AM-MSCs 2.90 (median). For WJ-MSCs 
for term samples mean MLR ratio was 2.43 and for preterm 
median ratio was 7.82. In statistical evaluation (the Wil-
coxon test ), the average decline did not differ significantly 
between AM-MSCs and WJ-MSCs.
DISCUSSION
Since 1961 when James Till, a biophysicist, and Ernest 
McCulloch, a haematologist, described their accidental 
findings which demonstrated the existence of rare cells that 
can proliferate and rebuild hematopoietic lineages, stem cells 
research was seeping towards the very centre of scientific 
Figure 2. The effect of adding term and preterm AM-MSC’s to MLR, 
Addition of term MSC’s leads to significant decline in lymphocytes 
proliferation with p = 0.005 (Wilcoxon test). The effect of preterm cells 
is equally good
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world [12]. Later, they defined stem cells as those, with the 
capacity to both self-renew and differentiate to various adult 
cells [13]. Researchers had to overcome tremendous obstacles 
to push knowledge to the point where we stand today. The 
history of stem cell research is a line of battles waged not 
only at the laboratory bench, but also on the field of ethics. In 
2016 the international guidelines for development of research 
and the clinical application of stem cell science has been fi-
nally accepted [14]. The recent advance in clinical translation 
of basic stem cell research is mainly based on following types 
of human cells: embryonic stem cells (ESCs) or induced pluri-
potent stem cells (iPSCs) and mesenchymal stem cells. Main 
legal and ethical questions concerning the use stem cells 
are issues affecting creation of human embryos for research 
purpose only (ESCs), potential oncogenesis (ESCs and iPSCs) 
and invasive procedures such as bone marrow aspiration 
or liposuction needed to obtain these cells (MSCs) [15–19]. 
Even though mitochondrial-replacement techniques 
(MRT) already has been used to replace dysfunctional mi-
tochondria in human egg with ones obtained from healthy 
donors in United Kingdom, many ethics warn it may lead to 
return of eugenic experiments. Similar questions arise con-
cerning possible injuries and comorbidities of bone marrow 
and adipose tissue donors. Recently, researchers focus on 
perinatal tissues like Wharton Jelly and amniotic membrane. 
Those tissues were proven to contain vast amount of mesen-
chymal stem cells [2, 20] and comparing with other sources 
does not evoke ethical issues because typically fetal tissues 
are disposed as medical waste and MSCs derivation does not 
require any additional procedures for the patients. Increas-
ing donor age is another factor that negatively affects the 
immunoregulatory properties of both adipose and bone 
marrow derived mesenchymal stem cells [21].
The frequency of MSCs in adipose tissue and bone mar-
row is about 3% and 0.001% of nucleated cells, respectively. 
It is not sufficient enough to dream about treating rapidly 
deteriorating patients [22–24]. Our data confirms previous 
findings that fetal tissues can be rich source of autologous 
MSCs, providing enough material for treatment even within 
hours from the delivery (with typical doses of 1 mln/kg) and 
sustainable source for continuing of the therapy. 
Fetal MSCs posses higher proliferative potential and 
less typical signs of senescence at an early stage in com-
parison to adult ASCs [7]. MSCs derived from Wharton Jelly 
are known for their ability to modulate immune response 
and have been successfully used in therapy of acute liver 
failure [25] and ischemic stroke [9] and lung injury charac-
terized by alveolar damage [26]. In four year observation 
of patients with refractory systemic lupus erythematosus, 
no transplantation-related adverse events and the induc-
tion of clinical remission and improvement in organ func-
tion in drug-resistant SLE patients have been reported [27]. 
Recent publications demonstrate that WJ-MSCs has a higher 
proliferation rate, a greater expansion capability, enhanced 
neurotrophic factors gene expression and spontaneous 
tendency toward a neural lineage differentiation when com-
pared with MSCs from bone marrow [3].
More and more research concentrate on the effect of 
different culture conditions on the qualities of obtained 
cells. Lowering oxygen level < 5% was shown to have a be- 
neficial impact on WJ-MSCs. It improved their rate of pro-
liferation, and maintenance of stemness properties during 
the culture [1]. Such factors like maternal age, the distance 
of collected umbilical cord fragment from the placenta were 
also investigated. It was found that WJ-MSCs derived from the 
extreme cord segments are better source of MSCs compared 
with cells from the middle segment because of their higher 
proliferation rate and viability [28]. In the research on 100 term 
pregnancies, from five maternal age groups (20–45 years), 
reduced number of cells as well as the level of MSCs markers 
expression were reported in older mothers [29].
MSCs show promise for cellular therapy for various di- 
seases associated with inflammation or auto-immunological 
disorders. Despite fact that fetal MSCs have been shown to 
be non-tumorogenic [30], safety rules must be obeyed. MSCs 
were shown to interact with cancer cells, revoking them from 
a dormant state in breast cancer [31]. Other scientists consid-
er their activity as antitumor, because despite co-culture with 
MSCs enhanced survival of nutrient deprived breast cancer 
cells in vitro, at the same time it suppressed their tumori-
genicity which leads for the prevention of cancer recurrence 
[32]. Recent preclinical studies conducted on animal models 
prove a presumption that MSCs can be a tool in treating 
hypoxic-ischemic injury in neonates [33]. It was shown that 
transplantation of MSCs ameliorate inflammation-induced 
neuronal cellular degeneration, reduce microgliosis and pre-
vent reactive astrogliosis in rat neonates [34]. Additionally, 
preclinical research demonstrate that MSCs-based therapies 
have potential for protecting the developing lung from inju-
ry. In expert’s opinion the evidence supporting this potential 
therapeutic role has provided the basis for the initiation of 
phase I and II clinical trials in preterm neonates [35]. Based 
on these arguments, further clinical research is needed to 
ensure patient safety before MSCs application in treatment 
of premature neonates [36]. The cited research has been 
performed in animal model and according to authors best 
knowledge our results are the first confirming the efficacy 
of human premature MSCs. 
CONCLUSION 
Human Wharton Jelly and amniotic membrane derived 
mesenchymal stem cells can be easily obtained and cul-
tured from premature tissues. Presented results suggest 
that preterm fetal tissues contain MSCs which show similar 
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immunosuppressive capacity as ones from term preg-
nancies. Premature fetal MSCs from early third-trimester 
pregnancy have the capacity to inhibit proliferation of 
allo-activated lymphocytes in an in vitro transplantation 
model. In the future they may be potentially used to prevent 
immuno-dependent injuries in premature newborns. 
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